longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

AllianceBernstein

AB

35.5001.58% ( -0.570 )
Closed: Sep 16, 16:00:00 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

AllianceBernstein (AB)

AllianceBernstein Holding L.P. is a publicly owned investment manager. The firm provides its services to investment companies, pension and profit-sharing plans,...

Open
36.040
High
36.500
Low
35.290
Prev. Close
36.070
Volume
442.82K
Turnover
15.81M
Avg Price
35.710
Bid/Ask Ratio
--
Amplitude
3.35%
52wk High
41.241
Volume Ratio
1.81
Turnover Ratio
0.48%
52wk Low
34.076
Float Mkt Cap
3.28B
Market CapUSD
3.30B
P/ETTM
10.57
P/EDynamic
10.53
P/EStatic
--
EPSTTM
3.36
EPSDynamic
3.37
EPSStatic
--
BVPS
13.38
P/B
2.65
Circulating Supply
92.31M
Dividend YieldTTM
9.77%
DividendTTM
3.47
Shares
93.08M
Min lot size
1
Currency
USD

News

  • Market Beat · 5 hours ago

    AllianceBernstein Holding L.P. (NYSE:AB) Short Interest Update

  • PUBT · 14 hours ago

    Bio-Rad CFO Roop Lakkaraju joins Bernstein Insights Healthcare Leaders and Disruptors forum fireside chat

  • PUBT · 16 hours ago

    Kailera Therapeutics to join Bernstein Insights healthcare investor forum fireside chat

  • Unusual Whales · 2 days ago, 02:09 PM

    AB CarVal Expands Multifamily Construction Lending Exposure With $340 Million Loan Portfolio Acquisition

  • PUBT · Sep 10 at 08:07 PM

    AllianceBernstein AUM rises to $919 billion at Aug. 31, 2026

Posts

View more

Bullish vs. Bearish — Last 3 Months

1.9k followers · 0 opinions
BT
▲Bullish50%
50%Bearish▼
  • D
    Dolphin ResearchJan 21 at 04:53 PM

    SCHW: Steady Comfort for Seasoned Investors

    $Charles Schwab(SCHW.US) Q4 stayed steady and broadly in line. Revenue was a slight miss, mainly on lower BDA fees, but tight expense control drove an earnings beat.

    Notably, the core operating metrics tracked by Dolphin Research were solid and above Street expectations. They point to stable organic growth at Schwab. Key takeaways below.

    1) Two key metrics — NNA (net new assets) and NIM (net interest margin). At this stage, if you boil Schwab’s biz. down, the single most important lens is net additions to client assets...

    charlesSCHWAB charlesSCHWAB
    SCHW Earnings results (USD in ,00mns) 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25( C
    平均每笔交易$0.99 PFOF收入 占总收入:8.0% 交易量 交易佣金收入 占总营收:7.4% 免佣证券交易 平均每笔交易$0.94 隔离账户资金 隔离账户
    SCHW Client Accounts New signup and Attrition rate 15% Research New signup rate +14
    Schwab
  • B
    Boss's BossJan 17 at 02:46 AM

    Robinhood (HOOD) 周报:2026 年 1 月 8 日至 1 月 14 日动态复盘

    $Robinhood(HOOD.US) Overview This week (January 8 to January 14, 2026), Robinhood Markets Inc. (HOOD) performed relatively stable in the capital market, with its stock price slightly dropping from around $120.24 to $118.32, and trading volume slightly below average. The company continues to focus on product innovation and global expansion, but no major financial updates or events were seen. The overall dynamics are dominated by strategic layout, with market sentiment neutral to cautious, affected by crypto volatility and competition...

    Robinhood 投资周报
  • B
    Boss's BossDec 21, 2025 at 01:31 AM

    Recursion Pharmaceuticals (RXRX) 的最新股权结构

    $Recursion Pharmaceuticals(RXRX.US) has a distinctive equity structure characterized by **"backing from AI giants, clustering of well-known growth funds, and regular founder share reductions"**. As of the latest data in December 2025, here is a detailed summary of RXRX's institutional ownership and core team holdings: 1. Institutional Ownership Overview Institutional investors currently hold approximately 60% - 70% of RXRX's outstanding shares...

    Recursion Pioneering TechBio solutions in drug ldiscovery The future of TechBio